Long-Term Safety Extension Study of ACTIMMUNE® (Interferon γ-1b) in Children and Young Adults With Friedreich's Ataxia
Status:
Completed
Trial end date:
2017-03-31
Target enrollment:
Participant gender:
Summary
The purpose of this long term extension study is to evaluate the long-term safety of
ACTIMMUNE® (interferon-γ 1b) in participants with Friedreich's Ataxia (FA).